Kiniksa Pharmaceuticals officer sells 194k in stock
KNSA Stock | USD 20.98 0.15 0.71% |
About 66% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
Kiniksa Pharmaceuticals officer sells 194k in stock
Read at investing.com
Kiniksa Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kiniksa Pharmaceuticals Fundamental Analysis
We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Kiniksa Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Kiniksa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiniksa Pharmaceuticals Related Equities
KRON | Kronos Bio | 8.51 | ||||
GOSS | Gossamer Bio | 2.86 | ||||
ACLX | Arcellx | 0.66 | ||||
NUVL | Nuvalent | 0.52 | ||||
REPL | Replimune | 0.91 | ||||
LRMR | Larimar Therapeutics | 0.99 | ||||
NVCT | Nuvectis Pharma | 1.24 | ||||
SPRO | Spero Therapeutics | 1.69 | ||||
KURA | Kura Oncology | 2.10 | ||||
COGT | Cogent Biosciences | 2.39 | ||||
DAWN | Day One | 2.46 | ||||
BOLT | Bolt Biotherapeutics | 3.45 | ||||
VTYX | Ventyx Biosciences | 3.46 | ||||
CGEM | Cullinan Oncology | 4.01 | ||||
LYRA | Lyra Therapeutics | 4.76 | ||||
PHAT | Phathom Pharmaceuticals | 5.03 | ||||
GPCR | Structure Therapeutics | 6.89 | ||||
CHRS | Coherus BioSciences | 11.70 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |